Experience using dupilumab for pediatric atopic dermatitis at a tertiary care c enter: Inadequate response and adverse events.

A small but significant number of patients experienced treatment difficulties while on dupilumab. The risk of inadequate response to dupilumab and dupilumab-associated AEs should be discussed thoroughly with patients and their families prior to initiation.